TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Endothelial function (ICAM-1, t-PA:Ag, vWF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: RMMA episode index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep and respiratory outcomes
Primary endpoint: Nausea scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of participants correctly selecting hetastarch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in the number of micturitions per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern Electroretinogram (PERG) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Evoked Potential (VEP) recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADHD‐RS total score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of manipulations required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of X-rays taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to daily PEF monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical recurrences during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: whole-body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Collagen/epinephrine closure time (EPICT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: association between negative affect and craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PWV (a-f)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptance of cyclosporine as standard therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Failure of weaning process
Endpoint domain: Mortality/survival
Primary endpoint: withdrawal discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean amblyopic-eye VA letter score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in smoking urges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tungiasis-associated morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean tHcy concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numeric pain score at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until first request for PCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Weight Concerns Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Onset of eating disorders (EDs)
Endpoint domain: Mortality/survival
Primary endpoint: Underweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate probing pocket depth on single-rooted teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL1-β levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage overweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of simvastatin acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of occlusal restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of approximal restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating insulin-like growth factor I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma insulin-like growth factor binding protein 1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin-like growth factor binding protein 3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Complete resolution of CIN 2/3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Viral DNA clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 6-month MCS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 12-month GDS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SF-6D score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mood level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in AUC0-2 h FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in AUC0-2 h FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postoperative plasma concentration of AA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of ventilator-associated pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in NPRS scores from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression of periportal +/‐ bridging necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Hospital admissions
Endpoint domain: Adverse events/effects
Primary endpoint: Knowledge levels at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Chance to detect prostate cancer in a biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall success rate of restorations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI findings in provocative position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positional change values in MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum costoclavicular distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in lumen dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline BCVA letter score at month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who gained >=15 letters in BCVA at month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with BCVA of >=20/40 at month 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wanting
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improved skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Less need for help providing assistance
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Fewer behavioral occurrences
Endpoint domain: Adverse events/effects
Primary endpoint: Revascularizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tacrolimus Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean improvement of SSS-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean improvement of FSS-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of alpha-peaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: congestion score of the anterior segment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phagocytic and microbicidal activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC0‐tlast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous thrombosis incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Mean INR deviation after correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful completion of abortion
Endpoint domain: Mortality/survival
Primary endpoint: Viral load (VL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: decrease in haemoglobin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: onset of anesthetic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent biliary obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence rate of nursing errors
Endpoint domain: Adverse events/effects
Primary endpoint: IADL disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Steroid dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower ventilation at 100% work rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower oxygen pulse (O2 pulse) at 100%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher ventilation hyperinflation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of IgG-SFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgG anti-tetanus antibody levels in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total number of circulating IgA SFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transit time through the small intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Transit time along the ileocolonic junction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: SFFR (Site-specific Follow-up Frequency Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cosmetic cumulative results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faster drain removal
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Faster discharge
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: anxiety levels during induction of anesthesia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: plasma norepinephrine and epinephrine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma lactate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fluid requirements during the first postoperative day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: overall perception of case management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax of gemigliptin, LC15‐0636, and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of gemigliptin, LC15‐0636, and metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum S100b levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants receiving diabetic retinopathy screening examinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of exposure to infectious diseases
Endpoint domain: Adverse events/effects
Primary endpoint: Mycologic eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hardness of breasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total DCS score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: risk for requiring invasive ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: duration of noninvasive ventilation until pulmonary oedema resolved
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of total pABG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum 25D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: sporting ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NASre-achievement of sport level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tubular proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Odom's score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cervical joint ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to work status
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in prescribing and referral patterns by GPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deviation from target cup position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet count reduction (ΔPLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in TC/HDL ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in LDL/HDL ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regional Recurrence Rate (PRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Decrease in hs-CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hypogammaglobulinemia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LogMAR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: field global indices mean deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of proven and probable IFIs within 100 days of HSCT
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality within 100 days after HSCT
Endpoint domain: Mortality/survival
Primary endpoint: Impairment in decision making involving uncertainty
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blunted affective reactions to feedback
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nebulisation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marked and moderate improvement in vitiligo patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of blood slides positive for malaria parasites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of outpatient and inpatient cases diagnosed as malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average number of months spent in the healed state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of amputations
Endpoint domain: Mortality/survival
Primary endpoint: Average expected cost of treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prostate specific antigen decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dihydrotestosterone decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: No-reflow prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall subjective disturbance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of postoperative pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptoms after operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of postoperative atrophic gastritis and reflux esophagitis
Endpoint domain: Adverse events/effects
Primary endpoint: Mean decrease in plasma HIV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS for xerostomia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral moisture status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sick leave status after 5 years
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Recurrences of sick leave
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: peri-shock pauses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: no-flow time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: defibrillation safety
Endpoint domain: Adverse events/effects
Primary endpoint: Recognition of a good death
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Palliative care knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Meaning of life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pedometer steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P1 amplitude of the total mfERG response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Implicit time of the mfERG response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Life Years (LYs)
Endpoint domain: Mortality/survival
Primary endpoint: Net Monetary Benefit (NMB)
Endpoint domain: Resource use
Primary endpoint: Trait affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of episodes of no sensation on maximal stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to platelet recovery to greater than or equal to 20 x 10(9)/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Normoprolactinaemia achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: HIT-associated thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiplatelet factor 4/heparin IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Week 24 remission (MADRS>or=10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Week 24 complete remission (MADRS<or=5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Declining fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Increasing vigor
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximal flow rate (Qmax) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost of one additional quality-adjusted life year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: cost of one additional case of clinically significant improvement
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increase in large HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Decrease in intermediate HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in time to complete laparoscopic tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency increase in laparoscopic tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant satisfaction with at-home trainer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Larsen damage score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IC measurement as a PDT outcome criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes